Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations Meeting Abstract
| Authors: | Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; Kris, M. G.; Rudin, C. M.; Chan, J. M.; Yu, H. A. |
| Abstract Title: | Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557402062 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.8565 |
| Notes: | Meeting Abstract: 8565 -- MSK author Britney Forsyth's last name is misspelled on the original publication -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
